| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.03.23 | ARKO CORP.: ARKO Corp. Details Significant Updates Provided to Travel Center of America's Board on Superior Acquisition Proposal | 456 | GlobeNewswire (Europe) | RICHMOND, Va., March 29, 2023 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO) ("ARKO"), a Fortune 500 company and one of the largest convenience store operators in the United States, today issued a letter... ► Artikel lesen | |
| 29.03.23 | Christian Dior SE: Availability of the 2022 Annual report | 366 | GlobeNewswire (Europe) | AVAILABILITYOF THE 2022 ANNUAL REPORT Christian Dior 2022 Annual report (French version) has been filed with the « Autorité des marchés financiers » (AMF) on March 29, 2023 in ESEF format (European... ► Artikel lesen | |
| 29.03.23 | Teck Resources Ltd: Teck Trail Operations Announces Low-Carbon Refined Zinc | 345 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) ("Teck") announced today a new report outlining the extremely low carbon footprint... ► Artikel lesen | |
| 29.03.23 | Fluxys Belgium: Regulated information - 2022 results | 295 | GlobeNewswire (Europe) | 29 March 2023 6:15 p.m. - Regulated information: overview of the 2022 annual results Increase of consolidated net income to €83.7 million (2021: €75.5 million). Proposal to the Annual General Meeting... ► Artikel lesen | |
| 29.03.23 | Dyadic International, Inc.: Dyadic Reports 2022 Year End Results and Recent Company Progress | 167 | GlobeNewswire (Europe) | Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain... ► Artikel lesen | |
| 29.03.23 | Osisko Mining Inc.: Osisko Submits Windfall Environmental Impact Assesment | 558 | GlobeNewswire (Europe) | TORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- Osisko Mining Inc. (OSK:TSX. "Osisko" or the "Corporation") is pleased to announce that it has submitted the Environmental Impact Assessment Report for its... ► Artikel lesen | |
| 29.03.23 | Nanophase Technologies Corporation: Nanophase Reports Third Consecutive Year of Record Revenue for 2022 | 991 | GlobeNewswire (Europe) | - Another record year with 27% YOY growth - Delivered $37 Million in full year revenue - In Beauty Science markets, Solésence revenue is up 27% YOY while Active Pharmaceutical Ingredients (API) sales... ► Artikel lesen | |
| 29.03.23 | Beam Global Reports Fourth Quarter and Full Year 2022 Financial Results | 298 | GlobeNewswire (Europe) | SAN DIEGO, March 29, 2023 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM, BEEMW), (the "Company"), the leading provider of innovative sustainable products and technologies for electric vehicle (EV)... ► Artikel lesen | |
| 29.03.23 | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million | 663 | GlobeNewswire (Europe) | - In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 - Strategic financings strengthen the company's balance sheet in advance of potential commercialization of LUMRYZ... ► Artikel lesen | |
| 29.03.23 | Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH | 432 | GlobeNewswire (Europe) | The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH... ► Artikel lesen | |
| 29.03.23 | Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights | 173 | GlobeNewswire (Europe) | Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data are... ► Artikel lesen | |
| 29.03.23 | Snail, Inc. Reports Fourth Quarter & Full Year 2022 Financial Results | 235 | GlobeNewswire (Europe) | CULVER CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) ("Snail" or "the Company"), a leading, global independent developer and publisher of interactive digital entertainment... ► Artikel lesen | |
| 29.03.23 | BioPorto A/S: US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. | 214 | GlobeNewswire (Europe) | March 29, 2023Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for... ► Artikel lesen | |
| 29.03.23 | Kubient, Inc.: Kubient Reports Fourth Quarter and Full Year 2022 Results | 249 | GlobeNewswire (Europe) | NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- Kubient, Inc. (NasdaqCM: KBNT, KBNTW) ("Kubient" or the "Company"), a cloud-based software platform for digital advertising, today reported financial results... ► Artikel lesen | |
| 29.03.23 | Xos, Inc. Reports Fourth Quarter and Full Year 2022 Results | 291 | GlobeNewswire (Europe) | Revenue increased more than six times year-over-year Deliveries in 2022 were up by 525% to 275 units Expects to begin delivering gross margin positive units in the second quarter of 2023 LOS ANGELES... ► Artikel lesen | |
| 29.03.23 | Actelis Networks, Inc.: Actelis Networks Reports Fiscal Full Year 2022 | 571 | GlobeNewswire (Europe) | FREMONT, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for wide... ► Artikel lesen | |
| 29.03.23 | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies | 191 | GlobeNewswire (Europe) | BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData support... ► Artikel lesen | |
| 29.03.23 | Reed's, Inc.: Reed's Reports Fourth Quarter and Full Year 2022 Results and Reiterates Its 2023 Financial Outlook | 305 | GlobeNewswire (Europe) | - Q4 2022 Net Sales Grew 18% to a Record $15.0 million, Gross Margins Expanded +250bps and Operating Expenses Declined 10% - - Continued Double-Digit Net Sales Growth, Gross Margin Expansion and Operating... ► Artikel lesen | |
| 29.03.23 | IntelGenx Technologies Corp.: IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results | 379 | GlobeNewswire (Europe) | SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month... ► Artikel lesen | |
| 29.03.23 | Lightbridge Corporation: Lightbridge Provides Business Update and Announces Fiscal Year 2022 Financial Results | 559 | GlobeNewswire (Europe) | RESTON, Va., March 29, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the year ended December 31, 2022... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.298 |
| EVOTEC | 2.638 |
| TUI | 2.076 |
| NEL | 1.327 |
| BAYER | 1.148 |
| PLUG POWER | 1.143 |
| NVIDIA | 1.139 |
| RHEINMETALL | 1.061 |
| AMC ENTERTAINMENT | 1.035 |
| DEUTSCHE BANK | 961 |
| SIEMENS ENERGY | 936 |
| RENK GROUP | 874 |
| REDCARE PHARMACY | 727 |
| COMMERZBANK | 726 |
| HEIDELBERGER DRUCK | 701 |
| ALIBABA | 677 |
| VOLKSWAGEN | 671 |
| E.ON | 619 |
| BARRICK GOLD | 612 |
| BYD | 592 |
| RWE | 586 |
| SIEMENS | 565 |
| TESLA | 563 |
| DEUTSCHE LUFTHANSA | 560 |
| AIXTRON SE | 554 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
